CoChat

Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)

Open access
Brinton, Eliot A., Mason, R. Preston · 2017 · Lipids in Health and Disease

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

The omega-3 fatty acid eicosapentaenoic acid (EPA) has multiple actions potentially conferring cardiovascular benefit, including lowering serum triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) levels and potentially reducing key steps in atherogenesis. Dietary supplements are a common source of omega-3 fatty acids in the US, but virtually all contain docosahexaenoic acid (DHA) in addition to EPA, and lipid effects differ between DHA and EPA. Contrary to popular belief, no over-the-counter omega-3 products are available in the US, only prescription products and dietary supplements. Among the US prescription omega-3 products, only one contains EPA exclusively (Vascepa); another closely related prescription omega-3 product also contains highly purified EPA, but is approved only in Japan and is provided in different capsule sizes. These high-purity EPA products do not raise low-density lipoprotein cholesterol (LDL-C) levels, even in patients with TG levels >500 mg/dL, in contrast to the increase in LDL-C levels with prescription omega-3 products that also contain DHA. The Japanese prescription EPA product was shown to significantly reduce major coronary events in hypercholesterolemic patients when added to statin therapy in the Japan EPA Lipid Intervention Study (JELIS). The effects of Vascepa on cardiovascular outcomes are being investigated in statin-treated patients with high TG levels in the Reduction of Cardiovascular Events With EPA-Intervention Trial (REDUCE-IT).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12944-017-0415-8

Cites

Statistics

Figures

Fig. 1 Effect of Vascepa on lipid levels in patients with very high TG levels (≥500 and ≤2000 mg/dL) in the MARINE study. Shown are the median changes from baseline to week 12 in the intent-to-treat population [7]. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MARINE, Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week Study with an Open-label Extension; Non-HDL-C, non-high-density lipoprotein cholesterol; TG, triglyceride; Total C, total cholesterol
Fig. 1 Effect of Vascepa on lipid levels in patients with very high TG levels (≥500 and ≤2000 mg/dL) in the MARINE study. Shown are the median changes from baseline to week 12 in the intent-to-treat population [7]. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MARINE, Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week Study with an Open-label Extension; Non-HDL-C, non-high-density lipoprotein cholesterol; TG, triglyceride; Total C, total cholesterolCC BY · PubMed Central
Fig. 2 Effect of Vascepa on lipid levels in patients with high TG levels (≥200 and <500 mg/dL) despite LDL-C control while on statin therapy in the ANCHOR study. Shown are the median changes from baseline to week 12 in the intent-to-treat population [8]. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; TG, triglyceride; Total C, total cholesterol
Fig. 2 Effect of Vascepa on lipid levels in patients with high TG levels (≥200 and <500 mg/dL) despite LDL-C control while on statin therapy in the ANCHOR study. Shown are the median changes from baseline to week 12 in the intent-to-treat population [8]. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; TG, triglyceride; Total C, total cholesterolCC BY · PubMed Central
Fig. 3 Mean trough total EPA concentrations (±SD) in plasma at baseline and at EOT in Vascepa and Epadel studies [98]. The PK study examined Vascepa in healthy adult subjects [101]. MARINE evaluated Vascepa in patients with very high TG levels (≥500 and ≤2000 mg/dL) [7]. ANCHOR evaluated Vascepa in patients with high TG levels (≥200 and <500 mg/dL) despite LDL-C control while on statin therapy [8]. Finally, JELIS evaluated Epadel in Japanese patients with hypercholesterolemia (total cholesterol ≥250 mg/dL) with or without CAD [36]. EOT = 4 weeks for the phase 1 PK study and 12 weeks in the MARINE and ANCHOR studies. JELIS was an outcome study with a planned follow-up of 5 years. Baseline values were not subtracted from EOT values. CAD, coronary artery disease; EOT, end of treatment; EPA, eicosapentaenoic acid; JELIS, Japan EPA Lipid Intervention Study; LDL-C, low-density lipoprotein cholesterol; MARINE, Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week Study with an Open-label Extension; PK, pharmacokinetic; SD, standard deviation; TG, triglyceride
Fig. 3 Mean trough total EPA concentrations (±SD) in plasma at baseline and at EOT in Vascepa and Epadel studies [98]. The PK study examined Vascepa in healthy adult subjects [101]. MARINE evaluated Vascepa in patients with very high TG levels (≥500 and ≤2000 mg/dL) [7]. ANCHOR evaluated Vascepa in patients with high TG levels (≥200 and <500 mg/dL) despite LDL-C control while on statin therapy [8]. Finally, JELIS evaluated Epadel in Japanese patients with hypercholesterolemia (total cholesterol ≥250 mg/dL) with or without CAD [36]. EOT = 4 weeks for the phase 1 PK study and 12 weeks in the MARINE and ANCHOR studies. JELIS was an outcome study with a planned follow-up of 5 years. Baseline values were not subtracted from EOT values. CAD, coronary artery disease; EOT, end of treatment; EPA, eicosapentaenoic acid; JELIS, Japan EPA Lipid Intervention Study; LDL-C, low-density lipoprotein cholesterol; MARINE, Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week Study with an Open-label Extension; PK, pharmacokinetic; SD, standard deviation; TG, triglycerideCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 91 · Cited by 83

Research works printed but not linked: 4

  1. Nagahara Y, Motoyama S, Sarai M, Ito H, Kawai H, Miyajima K, Naruse H, Ishii J, Ozaki Y. The impact of eicosapentaenoic acid on prevention of plaque progression detected by coronary computed tomography angiography [abstract P5235]. Eur Heart J. 2016;37 suppl 1:1052.
  2. Toth PP, Bays HE, Brown WV, Tomassini JE, Wang C, Polis AB, Tershakovec AM. Cholesterol in remnant-lipoproteins as measured by different methods [poster]. In: March 14–16, 2015; San Diego, CA. Annual scientific sessions of the American college of cardiology. 2015.
  3. Lopez JAG, Ito MK. PLA chapter update: prescription fish oil and blue cross of Idaho. LipidSpin. 2010;8:32–4.
  4. Mason R, Sherratt S. Analysis of omega-3 fatty acid dietary supplements with respect to content: are they appropriate for patients? [abstract E21]. J Manag Care Spec Pharm. 2015;21:S34.

Metadata

Authors
Brinton, E. A., & Mason, R. P.
Affiliations
  • Foundation for Biomedical Research (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Brinton, Eliot A.
Venue
Lipids in Health and Disease
Published
2017-01-31
Volume
16
Issue
1
Pages
23-23
ISSN
1476-511X (ISSN-L)
OpenAlex
W2580464342
Cited by
83
References
91
Citations by year
2026: 1 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 6 · 2018: 10 · 2017: 7
FWCI
0.96
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Lipids in Health and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • Amarin Corporation
  • Amarin Pharma
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Aquaculture Nutrition and Growth
Keywords
eicosapentaenoic acid, omega-3 fatty acids, docosahexaenoic acid, hypertriglyceridemia, LDL cholesterol, non-HDL cholesterol, triglycerides, cardiovascular outcomes, statin therapy, atherogenesis
MeSH terms
Humans, Drug Prescriptions, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). https://app.cochat.ai/papers/10.1186/s12944-017-0415-8
The paper
Brinton, E. A., & Mason, R. P. (2017). Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids in Health and Disease. https://doi.org/10.1186/s12944-017-0415-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.